StockData
MiNK Therapeutics, Inc. logo

MiNK Therapeutics, Inc. (INKT) stock

INKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$8.84−0.45 (-4.79%)

Close on Nov 18, 2026Market cap $45.11MP/E –Yield –

MiNK Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

MiNK Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$11.99M. For fiscal 2025 it was -$12.64M. The highest annual figure on record is -$11.29M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$12.64M–
FY2024Dec 31, 2024-$11.29M–
FY2023Dec 31, 2023-$22.92M–
FY2022Dec 31, 2022-$30.95M–
FY2021Dec 31, 2021-$28.36M–
FY2020Dec 31, 2020-$14.64M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.22M–
Q1 FY2026Mar 31, 2026-$2.88M–
Q4 FY2025Dec 31, 2025-$2.71M–
Q3 FY2025Sep 30, 2025-$3.18M–
Q2 FY2025Jun 30, 2025-$4.05M–
Q1 FY2025Mar 31, 2025-$2.70M–
Q4 FY2024Dec 31, 2024-$2.50M–
Q3 FY2024Sep 30, 2024-$1.88M–
Q2 FY2024Jun 30, 2024-$3.07M–
Q1 FY2024Mar 31, 2024-$3.83M–
Q4 FY2023Dec 31, 2023-$5.50M–
Q3 FY2023Sep 30, 2023-$5.22M–
Q2 FY2023Jun 30, 2023-$6.34M–
Q1 FY2023Mar 31, 2023-$5.85M–
Q4 FY2022Dec 31, 2022-$7.89M–
Q3 FY2022Sep 30, 2022-$7.99M–
Q2 FY2022Jun 30, 2022-$7.70M–
Q1 FY2022Mar 31, 2022-$7.37M–
Q4 FY2021Dec 31, 2021-$6.36M–
Q3 FY2021Sep 30, 2021-$13.38M–
Q2 FY2021Jun 30, 2021-$5.61M–
Q1 FY2021Mar 31, 2021-$3.01M–
Q4 FY2020Dec 31, 2020-$1.52M–
Q3 FY2020Sep 30, 2020-$5.92M–

More MiNK Therapeutics figures

See a number that looks wrong?